{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:00:15Z","timestamp":1790650815934,"version":"4.1.0"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T00:00:00Z","timestamp":1657065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Cognitive impairment is among the core dimensions in schizophrenia and is a significant predictor of everyday functioning in people with schizophrenia. Given the enormous burden of schizophrenia, the search for its clinically relevant biomarkers is essential. Researchers have been trying to elucidate factors of cognitive impairment as well as personal performance, but the search is still ongoing. The aim of the study was to search for associations between BDNF, CRP, IL-6 and clinical symptoms, cognitive and personal performance in patients with paranoid schizophrenia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A total of 86 patients (53.5% women, mean age 31.1 \u00b1 6.5) with paranoid schizophrenia (F20.0; ICD-10) in remission were examined. Clinical and neuropsychological examination included the Positive and Negative Syndrome Scale, Personal and Social Performance Scale, Calgary Depression Scale for Schizophrenia and the Brief Assessment of Cognitive Function in Schizophrenia. IL-6, BDNF, CRP levels were determined in the patients' blood serum.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Cognitive impairment was revealed in 79.1% of patients and was more profound in patients with higher number of hospitalizations (<jats:italic>p<\/jats:italic> = 0.006). The average BDNF levels were 13.38 \u00b1 15.84 ng\/ml, CRP concentration was 2.09 \u00b1 2.54 mg\/l, and IL-6 levels were 12.14 \u00b1 5.88 pg\/ml. There were no differences in biomarker levels or BACS results in patients that had different antipsychotic therapy or differed in the presence of anticholinergic therapy. CRP levels were higher in patients with longer disease duration, lower age of onset, more impaired personal social performance and processing speed. IL-6 was higher in individuals with lower working memory scores. PANSS negative subscale score negatively correlated and PSP score positively correlated with most cognitive domains. A linear regression established that the first episode vs. multiple episodes of schizophrenia could statistically significantly predict personal and social performance and cognition, including speech fluency and planning, as well as CRP levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This study continues the search for biomarkers of schizophrenia and cognitive impairment in schizophrenia to improve the reliability of diagnosing the disorder and find new treatment approaches. The role of the number of psychoses experienced (first episode vs. multiple episodes of schizophrenia) in cognition, personal and social performance and inflammation is shown.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.943869","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:18:19Z","timestamp":1657124299000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":16,"title":["A Cross-Sectional Study on Associations Between BDNF, CRP, IL-6 and Clinical Symptoms, Cognitive and Personal Performance in Patients With Paranoid Schizophrenia"],"prefix":"10.3389","volume":"13","author":[{"given":"Egor","family":"Chumakov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariia","family":"Dorofeikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Tsyrenova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nataliia","family":"Petrova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,7,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/S0140-6736(09)60995-8","article-title":"Schizophrenia","volume":"374","author":"van Os","year":"2009","journal-title":"Lancet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1176\/appi.focus.20170046","article-title":"An update on promising biomarkers in schizophrenia","volume":"16","author":"Goldsmith","year":"2018","journal-title":"Focus Am Psychiatr Publ."},{"key":"B3","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1017\/S1092852918001414","article-title":"Cognition, social cognition, and self-assessment in schizophrenia: prediction of different elements of everyday functional outcomes","volume":"24","author":"Silberstein","year":"2019","journal-title":"CNS Spectr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.neubiorev.2010.07.001","article-title":"The relationship between neurocognition and social cognition with functional outcomes in schizophrenia: a meta-analysis","volume":"35","author":"Fett","year":"2011","journal-title":"Neurosci Biobehav Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1001\/jamapsychiatry.2020.4614","article-title":"Italian network for research on psychoses. Factors associated with real-life functioning in persons with schizophrenia in a 4-year follow-up study of the italian network for research on psychoses","volume":"78","author":"Mucci","year":"2021","journal-title":"JAMA Psychiatry."},{"key":"B6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.neubiorev.2013.11.006","article-title":"Inflammation and the two-hit hypothesis of schizophrenia","volume":"38","author":"Feigenson","year":"2014","journal-title":"Neurosci Biobehav Rev."},{"key":"B7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/nyas.13712","article-title":"Inflammation in psychiatric disorders: what comes first?","volume":"1437","author":"Bauer","year":"2019","journal-title":"Ann N Y Acad Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.3390\/brainsci11010058","article-title":"Neutrophil-to-lymphocyte, platelet-to-lymphocyte and monocyte-to-lymphocyte ratio in bipolar disorder","volume":"11","author":"Fusar-Poli","year":"2021","journal-title":"Brain Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/S2215-0366(14)00122-9","article-title":"Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment","volume":"2","author":"Khandaker","year":"2015","journal-title":"Lancet Psychiatry."},{"key":"B10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41380-018-0220-4","article-title":"Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis","volume":"24","author":"Orlovska-Waast","year":"2019","journal-title":"Mol Psychiatry."},{"key":"B11","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.psychres.2017.09.041","article-title":"Cognitive deficit in patients with paranoid schizophrenia: its clinical and laboratory correlates","volume":"262","author":"Dorofeikova","year":"2018","journal-title":"Psy Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2174\/1570159X15666171123201142","article-title":"Imaging the role of inflammation in mood and anxiety-related disorders","volume":"16","author":"Felger","year":"2018","journal-title":"Curr Neuropharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fpsyt.2020.00160","article-title":"The role of inflammation in the treatment of schizophrenia","volume":"11","author":"Fond","year":"2020","journal-title":"Front Psychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/diseases7010011","article-title":"The effects of exercise on IL-6 levels and cognitive performance in patients with schizophrenia","volume":"7","author":"G\u00f3mez-Rubio","year":"2019","journal-title":"Diseases."},{"key":"B15","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.bbi.2021.06.016","article-title":"Early life adversity, functional connectivity and cognitive performance in schizophrenia: the mediating role of IL-6","volume":"98","author":"King","year":"2021","journal-title":"Brain Behav Immun."},{"key":"B16","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s00406-014-0533-5","article-title":"Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation","volume":"265","author":"Frydecka","year":"2015","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B17","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fpsyt.2017.00221","article-title":"Interleukin-6 in schizophrenia-is there a therapeutic relevance?","volume":"8","author":"Borovcanin","year":"2017","journal-title":"Front Psychiatry."},{"key":"B18","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/mp.2015.87","article-title":"C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications","volume":"21","author":"Fernandes","year":"2016","journal-title":"Mol Psychiatry."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1971","DOI":"10.1017\/S0033291719001685","article-title":"Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis","volume":"49","author":"Bora","year":"2019","journal-title":"Psychol Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2014.07.025","article-title":"Neuroimmune biomarkers in schizophrenia","volume":"176","author":"Tomasik","year":"2016","journal-title":"Schizophr Res."},{"key":"B21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.2147\/NDT.S46799","article-title":"Design and validation of standardized clinical and functional remission criteria in schizophrenia","volume":"10","author":"Mosolov","year":"2014","journal-title":"Neuropsychiatric Dis Treatment."},{"key":"B22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"B23","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1600-0447.2000.tb10933.x","article-title":"Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning","volume":"101","author":"Morosini","year":"2000","journal-title":"Acta Psychiatr Scand."},{"key":"B24","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0920-9964(90)90005-R","article-title":"A depression rating scale for schizophrenics","volume":"3","author":"Addington","year":"1990","journal-title":"Schizophr Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.schres.2003.09.011","article-title":"The brief assessment of cognition in schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery","volume":"68","author":"Keefe","year":"2004","journal-title":"Schizophr Res."},{"key":"B26","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/schbul\/sbj053","article-title":"The NIMH-MATRICS consensus statement on negative symptoms","volume":"32","author":"Kirkpatrick","year":"2006","journal-title":"Schizophr Bull."},{"key":"B27","volume-title":"Scale for the Assessment of Negative Symptoms (SANS)","author":"Andreasen","year":"1983"},{"key":"B28","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.scog.2015.10.004","article-title":"The search for new biomarkers for cognition in schizophrenia","volume":"2","author":"Penad\u00e9s","year":"2015","journal-title":"Schizop Res Cogn."},{"key":"B29","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1177\/1073858412469444","article-title":"Is altered BDNF biosynthesis a general feature in patients with cognitive dysfunctions?","volume":"19","author":"Carlino","year":"2012","journal-title":"Neuroscientist."},{"key":"B30","doi-asserted-by":"publisher","first-page":"133870","DOI":"10.1016\/j.neulet.2018.10.015","article-title":"BDNF as a pharmacogenetic target for antipsychotic treatment of schizophrenia","volume":"726","author":"Han","year":"2020","journal-title":"Neurosci Lett."},{"key":"B31","doi-asserted-by":"publisher","first-page":"662407","DOI":"10.3389\/fpsyt.2021.662407","article-title":"BDNF as a biomarker of cognition in schizophrenia\/psychosis: an updated review","volume":"12","author":"Nieto","year":"2021","journal-title":"Front. Psychiatry."},{"key":"B32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jpsychires.2017.11.004","article-title":"Schizophrenia heterogeneity revisited: clinical, cognitive, and psychosocial correlates of statistically-derived negative symptoms subgroups","volume":"97","author":"Ahmed","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.psychres.2019.01.051","article-title":"Brain-derived neurotrophic factor is associated with cognitive impairments in first-episode and chronic schizophrenia","volume":"273","author":"Yang","year":"2019","journal-title":"Psychiatry Res."},{"key":"B34","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.psyneuen.2019.06.006","article-title":"Interaction of BDNF and cytokines in executive dysfunction in patients with chronic schizophrenia","volume":"108","author":"Xiu","year":"2019","journal-title":"Psychoneuroendocrinology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2018.02.034","article-title":"Cognitive impairments and low BDNF serum levels in first-episode drug-naive patients with schizophrenia","volume":"263","author":"Man","year":"2018","journal-title":"Psychiatry Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.biopsych.2011.04.013","article-title":"Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects","volume":"70","author":"Miller","year":"2011","journal-title":"Biol Psychiatry."},{"key":"B37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.schres.2014.03.005","article-title":"Cytokine function in medication-naive first episode psychosis: a systematic review and meta- analysis","volume":"155","author":"Upthegrove","year":"2014","journal-title":"Schizophr Res."},{"key":"B38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.bbi.2015.09.014","article-title":"Interaction of BDNF with cytokines in chronic schizophrenia","volume":"51","author":"Zhang","year":"2016","journal-title":"Brain Behav Immun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.schres.2015.04.004","article-title":"Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls","volume":"165","author":"Hope","year":"2015","journal-title":"Schizophr Res."},{"key":"B40","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.bbi.2018.09.016","article-title":"Inflammation in individuals with schizophrenia \u2013 implications for neurocognition and daily function","volume":"74","author":"Kogan","year":"2018","journal-title":"Brain Behav Immun."},{"key":"B41","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1097\/01.XME.0000522264.90841","article-title":"Relationship of serum interleukin-6 and cognitive functions in patients with schizophrenia, a case\u2013control study","volume":"24","author":"Abdel Mohsen","year":"2017","journal-title":"Middle East Current Psychiatry."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1093\/schbul\/sbw029","article-title":"Chronic peripheral inflammation is associated with cognitive impairment in schizophrenia: results from the multicentric FACE-SZ dataset","volume":"42","author":"Bulzacka","year":"2016","journal-title":"Schizophr Bull."},{"key":"B43","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.schres.2017.04.015","article-title":"Cytokines and C-reactive protein alterations with respect to cognitive impairment in schizophrenia and bipolar disorder: a systematic review","volume":"192","author":"Misiak","year":"2018","journal-title":"Schizophr Res."},{"key":"B44","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/08039488.2019.1688389","article-title":"The association of cognitive performance and IL-6 levels in schizophrenia is influenced by age and antipsychotic treatment","volume":"74","author":"Ribeiro-Santos","year":"2020","journal-title":"Nord J Psychiatry."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3389\/fimmu.2018.02230","article-title":"C-Reactive protein: higher during acute psychotic episodes and related to cortical thickness in schizophrenia and healthy controls","volume":"9","author":"Jacomb","year":"2018","journal-title":"Front Immunol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s00406-021-01237-z","article-title":"Increased peripheral inflammation in schizophrenia is associated with worse cognitive performance and related cortical thickness reductions","volume":"271","author":"North","year":"2021","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B47","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3389\/fpsyt.2016.00131","article-title":"Physical functional capacity and c-reactive protein in schizophrenia","volume":"7","author":"Szortyka","year":"2016","journal-title":"Front Psychiatry."},{"key":"B48","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.schres.2014.06.034","article-title":"Meta-analysis of cognitive performance in drug-na\u00efve patients with schizophrenia","volume":"158","author":"Fatouros-Bergman","year":"2014","journal-title":"Schizophr Res."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.psychres.2014.12.069","article-title":"Brain-derived neurotrophic factor (BDNF) and neurocognitive deficits in people with schizophrenia: a meta-analysis","volume":"226","author":"Ahmed","year":"2015","journal-title":"Psy Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.schres.2019.05.044","article-title":"Identifying schizophrenia subgroups using clustering and supervised learning","volume":"214","author":"Talpalaru","year":"2019","journal-title":"Schizophr Res."},{"key":"B51","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jpsychires.2018.09.010","article-title":"Leveraging genome-wide association and clinical data in revealing schizophrenia subgroups","volume":"106","author":"Yin","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1007\/s00406-018-0908-0","article-title":"Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort","volume":"269","author":"Fond","year":"2019","journal-title":"Eur Arch Psychiatry Clin Neurosci."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.schres.2017.06.021","article-title":"Duration of untreated psychosis and neurocognition in first-episode psychosis: a meta-analysis","volume":"193","author":"Bora","year":"2018","journal-title":"Schizophr Res."},{"key":"B54","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.schres.2012.09.019","article-title":"Relationship between metabolic syndrome and cognition in patients with schizophrenia","volume":"142","author":"Lindenmayer","year":"2012","journal-title":"Schizophr Res."},{"key":"B55","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jpsychires.2018.08.017","article-title":"Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells","volume":"105","author":"Stapel","year":"2018","journal-title":"J Psychiatr Res."},{"key":"B56","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.ejphar.2018.12.003","article-title":"Antipsychotics-induced metabolic alterations: recounting the mechanistic insights, therapeutic targets and pharmacological alternatives","volume":"844","author":"Singh","year":"2019","journal-title":"Eur J Pharmacol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"110097","DOI":"10.1016\/j.pnpbp.2020.110097","article-title":"Gut microbiota: an intermediary between metabolic syndrome and cognitive deficits in schizophrenia","volume":"106","author":"Zeng","year":"2021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.943869\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T16:18:22Z","timestamp":1657124302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.943869\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,6]]},"references-count":57,"alternative-id":["10.3389\/fpsyt.2022.943869"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.943869","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,6]]},"article-number":"943869"}}